Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial.

Deucravacitinib demonstrated significant and clinically meaningful improvements in PROs versus placebo in patients with active PsA and warrants further study. This article is protected by copyright. All rights reserved.